P glycoprotein: A new mechanism to control drug-induced nephrotoxicity

Experimental Nephrology

Volumn 6, Issue 2, 1998, Pages 89-97

  Del Moral, Raimundo G ^a   Olmo, Asuncion ^a   Aguilar, Mariana ^a   O'Vaue, Francisco ^a  

^a UNIVERSITY OF GRANADA   (Spain)

Author keywords

Angiotensin II; Cyclosporin A; Nephrotoxicity; P glycoprotein; Tacrolimus

Indexed keywords

AMIODARONE; AZIDOPINE; COLCHICINE; CYCLOSPORIN A; DACTINOMYCIN; DAUNORUBICIN; DOXORUBICIN; EMETINE; ETOPOSIDE; GLYCOPROTEIN P; MITHRAMYCIN; MITOMYCIN C; MITOXANTRONE; NIFEDIPINE; PACLITAXEL; PROGESTERONE; PROTEIN KINASE C; PUROMYCIN; QUINIDINE; RAPAMYCIN; TACROLIMUS; TENIPOSIDE; TOPOTECAN; VERAPAMIL; VINBLASTINE; VINCRISTINE;

COMPETITIVE INHIBITION; CYTOTOXICITY; DETOXIFICATION; DRUG PROTEIN BINDING; DRUG UPTAKE; ENZYME ACTIVITY; ENZYME SUBSTRATE COMPLEX; HUMAN; KIDNEY TUBULE; MEMBRANE TRANSPORT; MULTIDRUG RESISTANCE; NEPHROTOXICITY; NONHUMAN; PRIORITY JOURNAL; SHORT SURVEY;

EID: 0031887288     PISSN: 10187782     EISSN: None     Source Type: Journal    
DOI: 10.1159/000020510     Document Type: Short Survey

References (59)

1. Biedler JL Riehm H: Cellular resistance to actinomycin D in Chinese hamster cells in vitro: Cross-resistance, radioautographic and cytogenetic studies. Cancer Res 1970;30:1174-1184.
2. Gottesman MM, Pastan I, Ambudkar SV: P-glycoproteia and multidrug resistance. Curr Opm Genet Dev 1996;6:610-617.
3. Germann UA: P-glycoprotein: A mediator of multidrug resistance in tumour cells. Eur J Cancer [A] 1996;32:927-944.
4. Gottesman MM, Hrycyna CA, Schoenlein PV, Germann U A, Pastan I: Genetic analysis of the multidrug transporter. Annu Rev Genet 1995;29:607-649.
5. Higgins CF: ABC transporters: From microorganisms to man. Annu Rev Cell Biol 1992;8:67-113.
6. Gottesman MM, Pastan I: Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem 1993;62:385-427.
7. Hamada H, Tsuruo T: Characterization of the ATPase activity of the Mr 170,000 to 180,000 membrane glycoprotein (P-glycoprotein) associated with multidrug resistance in K562/ ADM cells. Cancer Res 1988;48:4926-4932.
8. Fine RL, Chambers TC, Sachs CW: P-glycoprotein, multidrug resistance and protein kinase C. Stem Cells 1996;14:47-55.
9. Chaudhary PM, Roninson IB: Activation of MDR1 (P-glycoprotein) gene expression m human cells by protein kinase C agonists. Oncol Res 1992;4:281-290.
10. Drew L, Groome N, Warr JR, Rumsby MG: Reduced daunomycin accumulation in drug-sensitive and multidrug-resistant human carcinoma KB cells following phorbol ester treatment: A potential role for protein-kinase-C in reducing drug influx. Oncol Res 1996;8:249-257.
11. Cloudheflin BA, McMasters RA, Osborn HT, Chambers TC: Expression, subcellular distribution and response to phorbol esters of protein-kinase-C (PKC) isoenzymes in drug-sensitive and multidrug-resistant KB cells: Evidence for altered regulation of PKC-alpha. Eur J Biochem 1996;239:796-804.
12. Germann UA, Chambers TC, Ambudkar SV, Licht T, Cardarelli CO, Pastan I, Gottesman MM: Characterization of phosphorylation defective mutants of human P-glycoprotein expressed in mammalian cells. J Biol Chem 1996;271:1708-1716.
13. Goodfellow HR, Sardini A, Ruetz S, Callaghan R, Gros P, McNaughton PA, Higgins CF: Protem-kinase-C-mediated phosphorylation does not regulate drug transport by the human multidrug resistance P-glycoprotein. J Biol Chem 1996;271:13668-13674.
14. Cordon-Cardo C, O'Brien JP, Casals D, Bertino JR, Melamed MR: P-glycoprotein expression in human tumours and normal tissues. J Histochem Cytochem 1990;38:1277-1281.
15. Cordon-Cardo C, O'Brien JP, Casals D, Rittman-Giaver L, Briedler JL, Melamed MR, Bertmo JR: Mutidrug resistance gene (P-giycoprotein) is expressed by endothelial cells at blood-brain barrier sites. Proc Natl Acad Sci USA 1989;86:695-698.
16. Litcht T, Pastan I, Gottesman MM, Herrmann F: P-glycoprotein-mediated multidrug resistance in normal and neoplastic hematopoietic cells. Ann Hematol 1994;69:159-171.
17. Klimecki WT, Futscher BW, Grogan TM, Dalton WS: P-glycoprotein expression and function in circulating blood cells from normal volunteers. Blood 1994;83:2451-2458.
18. Smit JJM, Schuikel AH, Mol CAAM, Majoor D, Mooi WJ, Jongsman APM, Lincke CR, Borst P: Tissue distribution of the human MDR3 P-glycoprotein. Lab Invest 1994;71:638-649.
19. Vanhelvoort A, Smith AJ, Sprong H, Fritzsche I, Schinkel AH, Borst P, Vanmeer G: mdrl P-glycoprotein is a lipid translocase of broad specificity, while mdr3 P-glycoprotein specifically translocates phosphatidylcholine. Cell 1996;87:507-517.
20. Mayer U, Wagenaar E, Beijnen JH, Smit JW, Meijer DKF, Vaanasperen J, Borst P, Schinkel AH: Substantial excretion of digoxin via the intestinal mucosa and prevention of long-term digoxin accumulation in the brain by the mdrlA P-glycoprotein. Br J Pharmacol 1996;119:1038-1044.
21. Ueda K, Okamura N, Hirai M, Tanigawara Y, Saeki T, Kioka N, Komano T, Hori R: Human P-glycoprotein transports cortisol, aldosterone, and dexamethasone. but not progesterone. J Biol Chem 1992;267:2428-24252.
22. Twentyman PR: Cyclosporins as drug resistance modifiers. Biochem Pharmacol 1992;43:109-117.
23. Broeks A, Gerrard B, Allikmets R, Dean M, Plasterk RHA: Homologues of the human multidrug resistance genes MRP and MDR contribute to heavy metal resistance in the soil nematode Caenorhabditis elegans. EMBO J 1996;15:6132-6143.
24. Garcia del Moral R, O'Valle F, Andújar M, Aguilar M, Lucena MA, López-Hidalgo IL, Ramirez C, Medina-Cano MT, Aguilar D, Gomez-Morales M: Relationship between P-glycoprotein expression and cyclosporin A in kidney. An immunohistological and cell culture study. Am J Pathol 1995;146:398-408.
25. Leveille-Webster CR, Arias IM: The biology of the P-glycoproteins. J Membr Biol 1995;143:89-102.
26. Lanning CL, Fine RL, Sachs CW, Rao US, Corcoran JJ, Aboudonia MB: Chlorpyrifos oxon interacts with the mammalian multidrug resistance protein, P-glycoprotein. J Toxicol Environ Health 1996;47:395-407.
27. Axiotis CA, Guarch R, Merino MJ, Laporte N, Neumann RD: P-glycoprotein expression is increased in human secretory and gestational endometrium. Lab Invest 1991;65:577-581.
28. Fidd FJ, Bom ER, Chen H, Munhy S, Mathur SN: Esterification of plasma membrane cholesterol and triacylglycerol-rich lipoprotein secretion in CaCo-2 cells: Possible rote of P-glyccprotein. J Lipid Res 1995;36:1533-1543.
29. Borst P, Schinkel AH: What have we learnt thus far from mice with disrupted P-glycoprotein genes? Eur J Cancer [A] 1996;32:985-990.
30. Sharom FJ, DiDiodato G, Yu X, Ashbourne KJD: Interaction of the P-glycoprotein multidrug transporter with peptides and ionophores. J Biol Chem 1995;270:10334-10341.
31. Chong ASF, Markham PN, Gebel HM, Bines SD, Coon JS: Diverse multidrug-resistancemodification agents inhibit cytolytic activity of natural killer cells. Cancer Immunol Immunother 1993;36:133-139.
32. Gruol DJ, Bourgeois S: Expression of the mdr 1 P-glycoprotein gene: A mechanism of escape from glucocorticoid-induced apoptosis. Biochem Cell Biol 1994;72:561-571.
33. Geyp M, Ireland CM, Pittman SM: Resistance to apoptotic cell death in a drug resistant T-cell leukemia cell line. Leukemia 1996;10:447-455.
34. Wei LY, Roepe PD: Low external pH and osmotic shock increase the expression of human MDR protein. Biochemistry 1994;33:7229-7238.
35. Higgins CF: P-glycoprotein and cell volume-activated chloride channels. J Bioenerg Biomembr 1995;27:63-70.
36. Zhang L, Sachs CW, Fu HW, Fine RL, Casey PJ: Characterization of prenylcysteines that interact with P-glycoprotein and inhibit drug transport in tumour cells. J Biol Chem 1995;270:22859-22865.
37. Bendayan R: Renal drug transport: A review: Pharmacotherapy 1996;16:971-985.
38. Belloreuss E, Ernest S: Expression and function of P-glycoprotein in human mesangial cells. Am JPhysiol 1994;36:C1351-C1358.
39. Ernest S, Belloureuss E: Xenobiotic transport differences in mouse mesangial cell clones expressing Mdr1 and Mdr3. Am J Physiol 1996;39:C910-C919.
40. Bennett WM, DeMattos A, Meyer MM, Andoh T, Barry JM: Chronic cyclosporine nephropathy: The Achilles heel of immunosuppressive therapy. Kidney Int 1996;50:1089-1100.
41. Kim WJ, Kaheki Y, Kinoshita H, Arao S, Fukumoto M, Yoshida O: Expression patterns of multidrug-resistance (MDR1), multidrug resistance-associated protein (MRP), glutathione-S-transferase π (GST-π) and DNA topoisomerase II (TOPO II) genes in renal cell carcinomas and normal kidney. J Urol 1996;156:506-511.
42. Jette L, Beaulieu E, Leclerc JM, Beliveau R: Cyclosporine A treatment induces overexpression of P-glycoprotein in the kidney and other tissues. Am J Physiol 1996;39:F756-F765.
43. Schramm U, Fricker G, Wenger R, Miller DS: P-glycoprotein mediated secretion of a fluorescent cyclosporine analog by teleost renal proximal tubules. Am J Physiol 1995;37:F46-F52.
44. Gomez-Morales M, Bustos M, Montes A, Andújar M, Medina-Cano MT, Ramírez C, O'Valle F, Aguilar D, Aneiros J, Garcia del Moral R: Influence of intarenal deposits of cyclosporin A on acute renal transplant rejection. Nephron 1995;70:402-409.
45. Boguski MS, McCormick F: Proteins regulating Ras and its relatives. Nature 1993;366:643-654.
46. Chin KV, Ueda K, Pastan I, Gottesman MM: Modulation of activity of the promoter of the human mdr1 gene by ras and p53. Science 1992;255:459-462.
47. Ong ACM, Fine LG: Loss of glomerular function and tubulointerstitial fibrosis: Cause or effect? Kidney Int 1994;45:345-351.
48. Tang WW, Ulich TR, Lacey DL, Hill DC, Qi MY, Kaufman SA, Van GY, Tarpley JE, Yee JS: Platelet-derived growth factor BB induces renal tubulointerstitial myofibroblast formation and tubulointerstitial fibrosis. Am J Pathol 1996;148:1169-1180.
49. Kon V, Hunley TE, Fogo A: Combined antagonism of endothelin A/B receptors links endothelin to vasoconstriction whereas angiotensin II effects fibrosis: Studies in chronic nephrotoxicity-in rats. Transplantation 1995;60:89-95.
50. Stillamn IE, Andoh TF, Burdmann EA, Bennett WM, Rosen S: FK506 nephrotoxicity: Morphologic and physiological characterization of a rat model. Lab Invest 1995;73:794-803.
51. Okuda M, Kawahara Y, Nakayama I, Okamoto Y: Angiotensin-II induces Ras activation via At1 receptors in vascular smooth muscle cells (abstract). Circulation 1995;92:821.
52. Arai H, Escobedo JA: Angioteasin-II type-1 receptor signals through raf-1 by a protein kinase C-dependent, ras-independent mechanism. Mol Pharmacol 1996;50:522-528.
53. Stromaskaya TP, Grigorian IA, Ossovskaya VS, Rybalkina EY, Chumakov PM, Kopnin BP: Cell specific effects of ras oncogene and protein kinase C agonist TPA on P-glycoprotein function. FEBS Lett 1995;368:373-376.
54. Li SF, Janosh P, Tanji M, Rosenfeld GC, Waymire JC, Mischak H, Kolch W, Sedivy JM: Regulation of Raf-1 kinase activity by the 143-3-family of proteins. EMBO J 1995;14:685-696.
55. Zubiaur M, Forman LW, Stice LL, Faller DV: A role for activated P21 (Ras) in inhibition regulation of platelet-derived growth factor (PDGF) type-beta receptor activation. Onccgene 1996;12:1213-1222.
56. Deuel TF, Kim HRC: Pleiotropic effects of PDGF suggest new targets for cancer therapy. Antibody Immunoconjug Radiopharm 1995;8:333-340.
57. Ostad M, Shu WP, Kong L, Liu BCS: Ha-ras oncogene expression abrogates a pH-dependent endonuclease activity of apoptosis in normal rat kidney Cells. Cancer Lett 1996;98:175-182.
58. Evers R, Zaman GJR, Vandeemter L, Jansen H, Calafat J, Oomen LCJM, Elferink RPJO, Borst P, Schinkel AH: Basolateral localization and export activity of the human multidrug resistance-associated protein in polarized pig kidney cells. J Clin Invest 1996;97:1211-1218.
59. Sugawara I, Akiyama S, Scheper RJ, Itoyama S: Lung resistance protein (LRP) expression in human normal tissues in comparison with that of MDR1 and MRP. Cancer Lett 1997;112:23-31.